Incyte Corporation (INCY) CEO Hervé Hoppenot on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
Incyte Earnings Miss Expectations; Tightens Outlook For Top ProductInvestors Business Daily • 11/05/20
Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 11/05/20
More than 40 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual MeetingBusiness Wire • 11/04/20
ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid ArthritisPRNewsWire • 11/02/20
Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion DealSeeking Alpha • 11/01/20
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia AreataPRNewsWire • 10/30/20
Incyte (INCY) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/29/20
Pooled Results from Incyte's TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life AssessmentsBusiness Wire • 10/29/20
Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring OxygenPRNewsWire • 10/08/20
Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based TherapeuticsBusiness Wire • 10/05/20
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic DermatitisPRNewsWire • 09/18/20
Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin LymphomasBusiness Wire • 09/17/20
Eli Lilly, Incyte Combine Covid Drug With Gilead's, Post Positive DataInvestors Business Daily • 09/14/20
Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery timeMarket Watch • 09/14/20